CY1119031T1 - Βακτηριακως λαμβανομενα, ανεπαφα μινικυτταρα που συμπεριλαμβανουν ρυθμιστικο rna - Google Patents
Βακτηριακως λαμβανομενα, ανεπαφα μινικυτταρα που συμπεριλαμβανουν ρυθμιστικο rnaInfo
- Publication number
- CY1119031T1 CY1119031T1 CY20171100476T CY171100476T CY1119031T1 CY 1119031 T1 CY1119031 T1 CY 1119031T1 CY 20171100476 T CY20171100476 T CY 20171100476T CY 171100476 T CY171100476 T CY 171100476T CY 1119031 T1 CY1119031 T1 CY 1119031T1
- Authority
- CY
- Cyprus
- Prior art keywords
- minicators
- bacterius
- shutting
- continuous
- including regulatory
- Prior art date
Links
- 230000001105 regulatory effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11021—Polo kinase (2.7.11.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Manufacturing & Machinery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90907407P | 2007-03-30 | 2007-03-30 | |
| EP08828079.7A EP2145002B1 (en) | 2007-03-30 | 2008-03-26 | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119031T1 true CY1119031T1 (el) | 2018-01-10 |
Family
ID=40386454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100476T CY1119031T1 (el) | 2007-03-30 | 2017-05-02 | Βακτηριακως λαμβανομενα, ανεπαφα μινικυτταρα που συμπεριλαμβανουν ρυθμιστικο rna |
Country Status (17)
| Country | Link |
|---|---|
| EP (5) | EP2145002B1 (https=) |
| JP (1) | JP5167338B2 (https=) |
| CN (2) | CN105854029B (https=) |
| AU (1) | AU2008291833B2 (https=) |
| CA (3) | CA2933978C (https=) |
| CY (1) | CY1119031T1 (https=) |
| DK (2) | DK2145002T3 (https=) |
| ES (2) | ES2534435T3 (https=) |
| HR (2) | HRP20150328T1 (https=) |
| LT (1) | LT2865755T (https=) |
| MX (1) | MX2009010411A (https=) |
| NZ (1) | NZ580487A (https=) |
| PL (2) | PL2145002T3 (https=) |
| PT (2) | PT2145002E (https=) |
| SG (2) | SG10201804257RA (https=) |
| SI (2) | SI2865755T1 (https=) |
| WO (1) | WO2009027830A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE024999T2 (en) | 2004-08-26 | 2016-02-29 | Engeneic Molecular Delivery Pty Ltd | Introducing functional nucleic acids into mammalian cells with bacterial intact minicells |
| HRP20150328T1 (hr) * | 2007-03-30 | 2015-05-22 | Engeneic Molecular Delivery Pty Ltd. | Bakterijski dobivene, intaktne mini-stanice koje obuhvaä†aju funkcionalnu nukleinsku kiselinu, bez plazmida, za in vivo dopremu do stanica sisavaca |
| DE102009017908A1 (de) * | 2009-04-17 | 2010-10-21 | Kist-Europe Forschungsgesellschaft Mbh | Vektor für den Transport von mikrobiologischen Organismen zu Krankheitsherden |
| WO2011034421A1 (en) * | 2009-09-16 | 2011-03-24 | Stichting Het Nederlands Kanker Instituut | Fra-1 target genes as drug targets for treating cancer |
| RU2664698C2 (ru) | 2011-12-13 | 2018-08-21 | Энджинеик Молекьюлар Деливери Пти Лтд | Полученные из бактерий интактные мини-клетки для доставки лекарственных средств к опухолям мозга |
| US9006200B2 (en) | 2013-03-13 | 2015-04-14 | Asbestos Diseases Research Foundation | MicroRNA-based approach to treating malignant pleural mesothelioma |
| AP2016009153A0 (en) | 2013-10-04 | 2016-04-30 | Engeneic Molecular Delivery Pty Ltd | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
| AU2015326407C1 (en) * | 2014-10-03 | 2021-06-24 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| CA3039010A1 (en) | 2016-10-06 | 2018-04-12 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
| EP3615659A4 (en) | 2017-04-28 | 2021-01-06 | Agrospheres, Inc. | COMPOSITIONS AND METHODS OF ENCAPSULATION AND SCALABLE DELIVERY OF AGROCHEMICALS |
| WO2018201160A1 (en) | 2017-04-28 | 2018-11-01 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| CA3073449A1 (en) | 2017-09-25 | 2019-03-28 | Agrospheres, Inc. | Compositions and methods for scalable production and delivery of biologicals |
| EP3826654A4 (en) | 2018-07-23 | 2022-07-06 | EnGeneIC Molecular Delivery Pty Ltd | COMPOSITIONS COMPRISING MINICELLS OF BACTERIAL ORIGIN AND THEIR METHODS OF USE |
| AU2020205040A1 (en) | 2019-01-04 | 2021-08-12 | Engeneic Molecular Delivery Pty Ltd | Encapsulated glycolipid antigens for treatment of neoplastic diseases |
| US20230044257A1 (en) * | 2019-12-23 | 2023-02-09 | Agrospheres, Inc. | Compositions and methods for enhanced uptake of active ingredients for animal health and nutrition |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4496778A (en) | 1983-10-03 | 1985-01-29 | Exxon Research & Engineering Co. | Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO2000067776A1 (en) | 1999-05-11 | 2000-11-16 | Ortho-Mcneil Pharmaceuticals, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| JP4458846B2 (ja) | 2001-10-15 | 2010-04-28 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏにおけるＤＮＡ導入および遺伝子療法のためのベクターとしての完全なミニ細胞 |
| US20040053289A1 (en) * | 2002-09-09 | 2004-03-18 | The Regents Of The University Of California | Short interfering nucleic acid hybrids and methods thereof |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| DK1694361T3 (da) | 2003-12-09 | 2011-06-06 | Engeneic Molecular Delivery Pty Ltd | Målrettet levering til ikke-phagocytiske pattedyrceller via bakterielt afledte intakte miniceller |
| DK2992901T3 (da) | 2004-02-02 | 2020-01-27 | Engeneic Molecular Delivery Pty Ltd | Sammensætninger og fremgangsmåder til målrettet in vitro- og in vivo-medicinlevering til pattedyrceller via bakterielt afledte intakte miniceller |
| HUE024999T2 (en) * | 2004-08-26 | 2016-02-29 | Engeneic Molecular Delivery Pty Ltd | Introducing functional nucleic acids into mammalian cells with bacterial intact minicells |
| HRP20150328T1 (hr) * | 2007-03-30 | 2015-05-22 | Engeneic Molecular Delivery Pty Ltd. | Bakterijski dobivene, intaktne mini-stanice koje obuhvaä†aju funkcionalnu nukleinsku kiselinu, bez plazmida, za in vivo dopremu do stanica sisavaca |
-
2008
- 2008-03-26 HR HRP20150328TT patent/HRP20150328T1/hr unknown
- 2008-03-26 SI SI200831798A patent/SI2865755T1/sl unknown
- 2008-03-26 SG SG10201804257RA patent/SG10201804257RA/en unknown
- 2008-03-26 CA CA2933978A patent/CA2933978C/en active Active
- 2008-03-26 EP EP08828079.7A patent/EP2145002B1/en active Active
- 2008-03-26 SI SI200831411T patent/SI2145002T1/sl unknown
- 2008-03-26 CA CA2682704A patent/CA2682704C/en active Active
- 2008-03-26 EP EP19172998.7A patent/EP3564372A1/en active Pending
- 2008-03-26 DK DK08828079.7T patent/DK2145002T3/en active
- 2008-03-26 EP EP12178465.6A patent/EP2532746A3/en not_active Withdrawn
- 2008-03-26 JP JP2010500390A patent/JP5167338B2/ja active Active
- 2008-03-26 LT LTEP15150129.3T patent/LT2865755T/lt unknown
- 2008-03-26 PL PL08828079T patent/PL2145002T3/pl unknown
- 2008-03-26 CA CA2844647A patent/CA2844647C/en active Active
- 2008-03-26 CN CN201610277472.0A patent/CN105854029B/zh active Active
- 2008-03-26 EP EP17153863.0A patent/EP3205724B1/en active Active
- 2008-03-26 PL PL15150129T patent/PL2865755T3/pl unknown
- 2008-03-26 PT PT88280797T patent/PT2145002E/pt unknown
- 2008-03-26 MX MX2009010411A patent/MX2009010411A/es active IP Right Grant
- 2008-03-26 EP EP15150129.3A patent/EP2865755B1/en active Active
- 2008-03-26 CN CN200880018076.XA patent/CN101715489B/zh active Active
- 2008-03-26 WO PCT/IB2008/002984 patent/WO2009027830A2/en not_active Ceased
- 2008-03-26 DK DK15150129.3T patent/DK2865755T3/en active
- 2008-03-26 AU AU2008291833A patent/AU2008291833B2/en active Active
- 2008-03-26 SG SG10201507969PA patent/SG10201507969PA/en unknown
- 2008-03-26 NZ NZ580487A patent/NZ580487A/en unknown
- 2008-03-26 PT PT151501293T patent/PT2865755T/pt unknown
- 2008-03-26 ES ES08828079.7T patent/ES2534435T3/es active Active
- 2008-03-26 ES ES15150129.3T patent/ES2626179T3/es active Active
-
2017
- 2017-05-02 CY CY20171100476T patent/CY1119031T1/el unknown
- 2017-05-02 HR HRP20170662TT patent/HRP20170662T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119031T1 (el) | Βακτηριακως λαμβανομενα, ανεπαφα μινικυτταρα που συμπεριλαμβανουν ρυθμιστικο rna | |
| CY1121657T1 (el) | Μεθοδοι και συνθεσεις για κατευθυνομενη απο rna τροποποιηση dna στοχου και για κατευθυνομενη απο rna ρυθμιση της μεταγραφης | |
| CY1119878T1 (el) | Μια μεθοδος για απομονωση πυρηνικων οξεων και ενα kit εξ' αυτης | |
| EA201070430A1 (ru) | Мутированные гены синтазы ацетогидроксикислот в brassica | |
| EP4549567A3 (en) | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof | |
| TR201904022T4 (tr) | Konakçı hücre modifikasyon yöntemleri. | |
| EA201201264A1 (ru) | Молекулы полинуклеотидов для регуляции генов у растений | |
| PL2240572T3 (pl) | Wykorzystanie rna dla przeprogramowania komórek somatycznych | |
| EA201291024A1 (ru) | Композиции эндорибонуклеаз и способы их использования | |
| BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
| CL2011002611A1 (es) | Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17. | |
| EA201791610A1 (ru) | Проникающие в клетку антитела | |
| EP4484573A3 (en) | Compositions and methods for genomic dna and gene expression analysis in single cells | |
| ATE540313T1 (de) | Identifizierung von keimbahnfähigen embryonischen stammzellen | |
| CY1116310T1 (el) | Αθικτα μικροκυτταρα βακτηριακης προελευσης που περιλαμβανουν ενα λειτουργικο νουκλεϊκο οξυ απαλλαγμενο απο πλασμιδιο για in vivo χορηγηση σε κυτταρα θηλαστικων | |
| GUO et al. | Effects of over-expression of macrophage migration inhibitory factor on the expression of interleukin-8 and martix metalloproteinase-9 of human cervical cancer SiHa cells | |
| NZ730667A (en) | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |